Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) insider Gabriel Brooks sold 2,923 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $6.50, for a total value of $18,999.50. Following the completion of the transaction, the insider now owns 10,979 shares in the company, valued at approximately $71,363.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Solid Biosciences Trading Down 1.2 %
Shares of SLDB opened at $5.63 on Thursday. Solid Biosciences Inc. has a 12-month low of $1.81 and a 12-month high of $15.05. The firm has a market capitalization of $217.32 million, a P/E ratio of -1.71 and a beta of 1.90. The firm has a 50-day moving average price of $7.67 and a 200 day moving average price of $8.11.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.05. Equities research analysts predict that Solid Biosciences Inc. will post -2.61 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Solid Biosciences
Analyst Upgrades and Downgrades
SLDB has been the subject of several recent research reports. William Blair raised Solid Biosciences to a “strong-buy” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. upgraded shares of Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their target price for the company from $10.00 to $15.00 in a research report on Monday, July 15th. Barclays decreased their price target on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a research note on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $15.67.
View Our Latest Stock Analysis on SLDB
About Solid Biosciences
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Read More
- Five stocks we like better than Solid Biosciences
- Bank Stocks – Best Bank Stocks to Invest In
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is a SEC Filing?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The Most Important Warren Buffett Stock for Investors: His Own
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.